Metabotropic glutamate 2/3 receptors and epigenetic modifications in psychotic disorders: A review

Current Neuropharmacology

Volumn 14, Issue 1, 2016, Pages 41-47

  Matriscianoa, Francesco ^a   Panaccione, Isabella ^c   Grayson, Danis R ^a   Nicoletti, Ferdinando ^b,d   Guidotti, Alessandro ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

DNA methylation; Epigenetics; MGlu receptors; Prenatal stress; Psychosis

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DNA METHYLTRANSFERASE 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR;

ARTICLE; BEHAVIOR CHANGE; BIPOLAR DISORDER; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; DNA MODIFICATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; HUMAN; MENTAL DISEASE; NEUROPATHIC PAIN; NONHUMAN; PRENATAL STRESS; PSYCHOSIS; SCHIZOPHRENIA; ANIMAL; FRONTAL LOBE; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; FRONTAL LOBE; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 84958549176     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159x13666150713174242     Document Type: Article

References (68)

1. [1][1] Guidotti, A.; Auta, J.; Davis, J.M.; Dong, E.; Grayson, D.R.; Veldic, M.; Zhang, X.; Costa, E. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology, 2005, 180, 191-205. http://dx.doi.org/10.1007/s00213-005-2212-8
2. [2][2] Grayson, D.R.; Guidotti, A. The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. Neuropsycho pharmacology, 2013, 38, 138-166. http://dx.doi.org/10.1038/npp.2012.125
3. [3][3] Dong, E.; Nelson, M.; Grayson, D.R.; Costa, E.; Guidotti, A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 13614-1369. http://dx.doi.org/10.1073/pnas.0805493105
4. Guidotti A.; Dong, E.; Kundakovic, M.; Satta, R.; Grayson, D.R.; Costa, E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol. Sci., 2009, 30, 55-60. http://dx.doi.org/10.1016/j.tips.2008.10.010
5. [5][5] Haig, D. The (dual) origin of epigenetics. Cold Spring Harb. Symp. Quant. Biol., 2004, 69, 67-70. http://dx.doi.org/10.1101/sqb.2004.69.67
6. [6][6] Campos, E.I.; Stafford, J.M.; Reinberg, D. Epigenetic inheritance: histone bookmarks across generations. Trends Cell. Biol., 2014, 24, 664-674. http://dx.doi.org/10.1016/j.tcb.2014.08.004
7. [7][7] McGowan, P.O.; Szyf, M. Environmental epigenomics: understanding the effects of parental care on the epigenome. Essays Biochem., 2010, 48, 275-287. http://dx.doi.org/10.1042/bse0480275
8. [8][8] Razin, A. CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J., 1998, 17, 4905-4908. http://dx.doi.org/10.1093/emboj/17.17.4905
9. [9][9] Bergmann, A.; Lane, M.E. HIDden targets of microRNAs for growth control. Trends Biochem Sci., 2003, 28, 461-463. http://dx.doi.org/10.1016/S0968-0004(03)00175-0
10. [10][10] Kuo, M. H.; Allis, C.D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays, 1998, 20, 615-626. http://dx.doi.org/10.1002/(SICI)1521-1878(199808)20:8%3C615::AID-BIES4%3E3.0.CO;2-H
11. [11][11] Nestler, E.J. Epigenetic mechanisms of depression. JAMA Psychiatry, 2014, 71, 454-456. http://dx.doi.org/10.1001/jamapsychiatry.2013.4291
12. [12][12] Veldic, M.; Kadriu, B.; Maloku, E.; Agis-Balboa, R.C.; Guidotti, A.; Davis, J.M.; Costa, E. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res., 2007, 91, 51-61. http://dx.doi.org/10.1016/j.schres.2006.11.029
13. [13][13] Costa, E.; Grayson, D.R.; Guidotti, A. Epigenetic downregulation of GABAergic function in schizophrenia: potential for pharmacological intervention? Mol. Interv., 2003, 3, 220-229. http://dx.doi.org/10.1124/mi.3.4.220
14. [14][14] Grayson, D.R.; Jia, X.; Chen, Y.; Sharma, R.P.; Mitchell, C.P.; Guidotti, A.; Costa, E. Reelin promoter hypermethylation in schizophrenia. Proc. Natl. Acad. Sci. U S A., 2005, 102, 9341-9346. http://dx.doi.org/10.1073/pnas.0503736102
15. [15][15] Petronis, A. The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. Biol. Psychiatry, 2004, 55, 965-970.
16. [16][16] McGowan, P.O.; Kato T. Epigenetics in mood disorders. Environ Health Prev Med., 2008, 13, 16-24. http://dx.doi.org/10.1007/s12199-007-0002-0
17. [17][17] Weinberger, D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry, 1987, 44, 660-669. http://dx.doi.org/10.1001/archpsyc.1987.01800190080012
18. [18][18] Keshavan, M.S.; Hogarty, G.E. Brain maturational processes and delayed onset in schizophrenia. Dev. Psychopathol., 1999, 11, 525-543. http://dx.doi.org/10.1017/S0954579499002199
19. [19][19] Fatemi, S. h.; Folsom, T.D. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull., 2009, 35, 528-548. http://dx.doi.org/10.1093/schbul/sbn187
20. [20][20] Markham, J.A.; Koenig, J I. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology, 2011, 214, 89-106. http://dx.doi.org/10.1007/s00213-010-2035-0
21. [21][21] Khashan, A.S.; Abel, K.M.; McNamee, R.; Pedersen, M.G.; Webb, R.T.; Baker, P.N.; Kenny, L.C.; Mortensen, P.B. Higher risk of offspring schizophrenia following antenatal maternal exposure to severe adverse life events. Arch. Gen. Psychiatry, 2008, 65, 146-152. http://dx.doi.org/10.1001/archgenpsychiatry.2007.20
22. [22][22] Giovanoli, S.; Engler, H.; Engler, A.; Richetto, J.; Voget, M.; Willi, R.; Winter, C.; Riva, M.A.; Mortensen, P.B.; Feldon, J.; Schedlowski, M.; Meyer, U. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science, 2013, 339, 1095-1099. http://dx.doi.org/10.1126/science.1228261
23. [23][23] Matrisciano, F.; Tueting, P.; Dalal, I.; Kadriu, B.; Grayson, D.R.; Davis, J.M.; Nicoletti, F.; Guidotti, A. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology, 2013, 68, 184-194. http://dx.doi.org/10.1016/j.neuropharm.2012.04.013
24. [24][24] Stevens, H.E.; Su, T.; Yanagawa, Y.; Vaccarino, F.M. Prenatal stress delays inhibitory neuron progenitor migration in the developing neocortex. Psychoneuroendocrinology, 2013, 38, 509-521. http://dx.doi.org/10.1016/j.psyneuen.2012.07.011
25. [25][25] Fine, R.; Zhang, J.; Stevens H E. Prenatal stress and inhibitory neuron systems: implications for neuropsychiatric disorders. Mol. Psychiatry, 2014, 19, 641-651. http://dx.doi.org/10.1038/mp.2014.35
26. [26][26] Lisman, J.E.; Coyle, J.T.; Green, R.W.; Javitt, D.C.; Benes, F.M.; Heckers, S.; Grace, A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci., 2008, 31, 234-242. http://dx.doi.org/10.1016/j.tins.2008.02.005
27. [27][27] Gonzalez-Burgos, G.; Lewis, D.A. GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr. Bull., 2008, 34, 944-961. http://dx.doi.org/10.1093/schbul/sbn070
28. [28][28] Dickerson, D.D.; Overeem, KA.; Wolff, A.R.; Williams, J.M.; Abraham, W.C.; Bilkey, D.K. Association of aberrant neural synchrony and altered GAD67 expression following exposure to maternal immune activation, a risk factor for schizophrenia. Transl. Psychiatry, 2014, 4, 418. http://dx.doi.org/10.1038/tp.2014.64
29. [29][29] Matrisciano, F.; Tueting, P.; Maccari, S.; Nicoletti, F.; Guidotti, A. Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice. Neuropsychopharmacology, 2012, 37, 929-938. http://dx.doi.org/10.1038/npp.2011.274
30. [30][30] Dong, E.; Dzitoyeva, S.G.; Matrisciano, F.; Tueting, P.; Grayson, D.R.; Guidotti, A. Brain-Derived Neurotrophic Factor Epigenetic Modifications Associated with Schizophrenia-like Phenotype Induced by Prenatal Stress in Mice. Biol. Psychiatry, 2015, 77, 589-596. pii: S0006-3223(14)00634-9.
31. [31][31] Dong, E., Ruzicka, W.B.; Grayson, D.R.; Guidotti, A. DNAmethyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients. Schizophr. Res., 2015, 167, 35-41. pii: S0920-9964(14)00599-4.
32. [32][32] Houston, I.; Peter, C.J.; Mitchell, A.; Straubhaar, J.; Rogaev, E.; Akbarian, S. Epigenetics in the human brain. Neuropsychopharmacology, 2013, 38, 183-197. http://dx.doi.org/10.1038/npp.2012.78
33. [33][33] Guidotti, A.; Auta, J.; Chen, Y.; Davis, J.M.; Dong, E.; Gavin, D.P.; Grayson, D.R.; Matrisciano, F.; Pinna, G.; Satta, R.; Sharma, R.P.; Tremolizzo, L.; Tueting, P. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology, 2011, 60, 1007-1016. http://dx.doi.org/10.1016/j.neuropharm.2010.10.021
34. [34][34] Mill, J.; Tang, T.; Kaminsky, Z.; Khare, T.; Yazdanpanah, S.; Bouchard, L.; Jia, P.; Assadzadeh, A.; Flanagan, J.; Schumacher, A., Wang, S.C.; Petronis, A. Epigenomic profiling reveals DNAmethylation changes associated with major psychosis. Am. J. Hum. Genet., 2008, 82, 696-711. http://dx.doi.org/10.1016/j.ajhg.2008.01.008
35. [35][35] Zhang, J.P.; Malhotra, A.K. Genetics of schizophrenia: What do we know? Curr. Psychiatr., 2013, 12, 24-33.
36. [36][36] Gavin, D.P.; Akbarian, S. Epigenetic and post-transcriptional dysregulation of gene expression in schizophrenia and related disease. Neurobiol. Dis., 2012, 46, 255-262. http://dx.doi.org/10.1016/j.nbd.2011.12.008
37. [37][37] Dong, E.; Gavin, D.P.; Chen, Y.; Davis, J. Upregulation of TET1 and downregulation of APOBEC3A and APOBEC3C in the parietal cortex of psychotic patients. Transl. Psychiatry, 2012, 2, 159. http://dx.doi.org/10.1038/tp.2012.86
38. [38][38] Guidotti, A.; Auta, J.; Davis, J.M.; Dong, E.; Gavin, D.P.; Grayson, D.R.; Sharma, R.P.; Smith, R.C.; Tueting, P.; Zhubi, A. Toward the identification of peripheral epigenetic biomarkers of schizophrenia. J. Neurogenet., 2014, 28, 41-52. http://dx.doi.org/10.3109/01677063.2014.892485
39. [39][39] Meyer, U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol. Psychiatry, 2014, 75, 307-315. http://dx.doi.org/10.1016/j.biopsych.2013.07.011
40. [40][40] Ribeiro, B.M.; do Carmo, M.R.; Freire, R.S.; Rocha, N.F.; Borella, V.C.; de Menezes, A.T.; Monte, A.S.; Gomes, P.X.; de Sousa, F.C., Vale, M.L.; de Lucena, D.F.; Gama, C.S.; Macedo, D. Evidences for a progressive microglial activation and increase in iNOS expression in rats submitted to a neurodevelopmental model of schizophrenia: reversal by clozapine. Schizophr. Res., 2013, 151, 12-19. http://dx.doi.org/10.1016/j.schres.2013.10.040
41. [41][41] Nicoletti, F.; Bockaert, J.; Collingridge, G.L.; Conn, P.J.; Ferraguti, F.; Schoepp D.D.; Wroblewski, J.T.; Pin, J.P. Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology, 2011, 60, 1017-1041. http://dx.doi.org/10.1016/j.neuropharm.2010.10.022
42. [42][42] (Schoepp) DD, D.D.; Marek, G.J. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr. Drug Targets CNS Neurol. Disord., 2002, 1, 215-225. http://dx.doi.org/10.2174/1568007024606177
43. [43][43] Cartmell, J.; Monn, J.A.; Schoepp, D.D. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology, 2000, 148, 423-429. http://dx.doi.org/10.1007/s002130050072
44. [44][44] Cartmell, J.; Monn, J.A.; Schoepp, D.D. The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur. J. Pharmacol., 2000, 400, 221-224. http://dx.doi.org/10.1016/S0014-2999(00)00423-4
45. [45][45] Moghaddam, B.; Adams, B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science, 1998, 281, 1349-1352. http://dx.doi.org/10.1126/science.281.5381.1349
46. [46][46] Olszewski, R.T.; Bzdega, T.; Neale, J.H. mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia. Schizophr. Res., 2012, 136, 160-161. http://dx.doi.org/10.1016/j.schres.2012.01.007
47. [47][47] Carter, K.; Dickerson, J.; Schoepp, D.D.; Reilly, M.; Herring, N.; Williams, J.; Sallee, F.R.; Sharp, J.W.; Sharp, F.R. The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis. Neuropharmacology, 2004, 47, 1135-1145. http://dx.doi.org/10.1016/j.neuropharm.2004.08.018
48. [48][48] Ago, Y.; Araki, R.; Yano, K.; Hiramatsu, N.; Kawasaki, T.; Chaki, S.; Nakazato, A.; Onoe, H.; Hashimoto, H.; Baba, A.; Takuma, K.; Matsuda, T. Activation of metabotropic glutamate 2/3 receptors attenuates methamphetamine-induced hyperlocomotion and increase in prefrontal serotonergic neurotransmission. Psychopharmacology, 2011, 217, 443-452. http://dx.doi.org/10.1124/mol.107.035170
49. [49][49] Benneyworth, M.A.; Xiang, Z.; Smith, R.L.; Garcia, E.E.; Conn, P.J.; Sanders-Bush, E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol., 2007, 72, 477-484. http://dx.doi.org/10.1124/mol.107.035170
50. [50][50] Marek, G.J.; Wright, R.A.; Schoepp, D.D.; Monn, J.A.; Aghajanian, G.K. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther., 2000, 292, 76-87.
51. [51][51] Winter, J.C.; Eckler, J.R.; Rabin, R.A. Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology, 2004, 172, 233-240. http://dx.doi.org/10.1007/s00213-003-1636-2
52. [52][52] Moreno, J.L.; Muguruza, C.; Umali, A.; Mortillo, S.; Holloway, T.; Pilar-Cuellar, F.; Mocci, G.; Seto, J.; Callado, L.F.; Neve, R.L.; Milligan, G.; Sealfon, S.C.; Lopez-Gimenez, J.F., Meana, J.J.; Benson, D.L.; Gonzalez-Maeso, J. Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5- HT2A・mGlu2) receptor heteromerization and its psychoactive behavioral function. J. Biol. Chem., 2012, 287, 44301-44319 http://dx.doi.org/10.1074/jbc.M112.413161
53. [53][53] Patil, S.T.; Zhang, L.; Martenyi, F.; Lowe, S.L.; Jackson, K.A.; Andreev, B.V.; Avedisova, A.S.; Bardenstein, L.M.; Gurovich, I.Y.; Morozova, M.A.; Mosolov, S.N.; Neznanov, N.G.; Reznik, A.M.; Smulevich, A.B.; Tochilov, V.A.; Johnson, B.G.; Monn, J.A.; Schoepp, D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med., 2007, 13, 1102-1107. http://dx.doi.org/10.1038/nm1632
54. Kinon, B.J.; Zhang, L.; Millen, B.A.; Osuntokun, O.O.; Williams, J.E.; Kollack-Walker, S.; Jackson, K.; Kryzhanovskaya, L.; Jarkova, N.; HBBI Study Group. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J. Clin. Psychopharmacol., 2011, 31, 349-355. http://dx.doi.org/10.1097/JCP.0b013e318218dcd5
55. [55][55] Stauffer, V.L.; Millen, B.A.; Andersen, S.; Kinon, B.J., Lagrandeur, L.; Lindenmayer, J.P.; Gomez, J.C. Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo. Schizophr. Res., 2013, 150, 434-441. http://dx.doi.org/10.1016/j.schres.2013.08.020
56. [56][56] Kurita, M.; Holloway, T.; Garcia-Bea, A.; Kozlenkov, A.; Friedman, A.K.; Moreno, J.L.; Heshmati, M.; Golden, S.A.; Kennedy, P.J.; Takahashi, N.; Dietz, D.M.; Mocci, G.; Gabilondo, A.M.; Hanks, J.; Umali, A.; Callado, L.F.; Gallitano, A.L.; Neve, R.L.; Shen, L.; Buxbaum, J.D.; Han, M. H.; Nestler, E.J.; Meana, J.J.; Russo, S.J.; Gonzalez-Maeso, J. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat. Neurosci., 2012, 15, 1245-1254. http://dx.doi.org/10.1038/nn.3181
57. [57][57] Kurita, M.; Moreno, J.L.; Holloway, T.; Kozlenkov, A.; Mocci, G.; García-Bea, A.; Hanks, J.B.; Neve, R.; Nestler, E.J.; Russo, S.J.; González-Maeso, J. Repressive epigenetic changes at the mGlu2 promoter in frontal cortex of 5-HT2A knockout mice. Mol. Pharmacol., 2013, 83, 1166-1175. http://dx.doi.org/10.1124/mol.112.084582
58. [58][58] Matrisciano, F.; Dong, E.; Gavin, D.P.; Nicoletti, F.; Guidotti, A. Activation of group II metabotropic glutamate receptors promotes DNA demethylation in the mouse brain. Mol. Pharmacol., 2011, 80, 174-182. http://dx.doi.org/10.1124/mol.110.070896
59. [59][59] Phiel, C.J.; Zhang, F.; Huang, E.Y.; Guenther, M.G.; Lazar, M.A.; Klein, P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem., 2001, 276, 36734-36741. http://dx.doi.org/10.1074/jbc.M101287200
60. [60][60] Aghajanian, G.K.; Marek, G.J. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res. Brain Res. Rev., 2000, 31, 302-312. http://dx.doi.org/10.1016/S0165-0173(99)00046-6
61. [61][61] González-Maeso, J.; Ang, R.L.; Yuen, T.; Chan, P.; Weisstaub, N.V.; Lopez-Giménez, J.F.; Zhou, M.; Okawa, Y.; Callado, L.F.; Milligan, G.; Gingrich, J.A.; Filizola, M.; Meana, J.J.; Sealfon, S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452, 93-97. http://dx.doi.org/10.1038/nature06612
62. [62][62] Fribourg, M.; Moreno, J.L.; Holloway, T.; Provasi, D.; Baki, L.; Mahajan, R.; Park, G.; Adney, S.K.; Hatcher, C.; Eltit, J.M.; Ruta, J.D.; Albizu, L.; Li, Z.; Umali, A.; Shim, J.; Fabiato, A.; MacKerell, A.D. Jr.; Brezina, V.; Sealfon, S.C.; Filizola, M.; Gonzalez-Maeso, J.; Logothetis, D.E. Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell, 2011, 147, 1011-1023. http://dx.doi.org/10.1016/j.cell.2011.09.055
63. [63][63] Moreno, J.L.; Muguruza, C.; Umali, A.; Mortillo, S.; Holloway, T.; Pilar-Cuéllar, F.; Mocci, G.; Seto, J.; Callado, L.F.; Neve, R.L.; Milligan, G.; Sealfon, S.C.; López-Giménez, J.F.; Meana, J.J.; Benson, D.L.; Gonzalez-Maeso, J. Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5- HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function. J. Biol. Chem., 2012, 287, 44301-44319. http://dx.doi.org/10.1074/jbc.M112.413161
64. 2 receptors in the adult offspring. J. Neurosci., 2011, 31, 1863-1872. http://dx.doi.org/10.1523/JNEUROSCI.4230-10.2011
65. [65][65] Holloway, T.; Moreno, J.L.; Umali, A.; Rayannavar, V.; Hodes, G.E.; Russo, S.J.; González-Maeso J. Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune syste. J. Neurosci., 2013, 33, 1088-1098. http://dx.doi.org/10.1523/JNEUROSCI.2331-12.2013
66. [66][66] Chiechio, S.; Caricasole, A.; Barletta, E.; Storto, M.; Catania, M.V.; Copani, A.; Vertechy, M.; Nicolai, R.; Calvani, M.; Melchiorri, D.; Nicoletti, F. L-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Mol. Pharmacol., 2002, 61, 989-996. http://dx.doi.org/10.1124/mol.61.5.989
67. [67][67] Chiechio, S.; Copani, A.; Zammataro, M.; Battaglia, G.; Gereau, R.W. 4th; Nicoletti, F. Transcriptional regulation of type-2 metabotropic glutamate receptors: an epigenetic path to novel treatments for chronic pain. Trends Pharmacol. Sci., 2010, 31, 153-160. http://dx.doi.org/10.1016/j.tips.2009.12.003
68. [68][68] Nasca, C.; Xenos, D.; Barone, Y.; Caruso, A.; Scaccianoce, S.; Matrisciano, F.; Battaglia, G.; Mathe, A.A.; Pittaluga, A.; Lionetto, L.; Simmaco, M.; Nicoletti, F. L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc. Natl. Acad. Sci. U S A., 2013, 110, 4804-4809. http://dx.doi.org/10.1073/pnas.1216100110